Systemic side effects of isolated limb perfusion with tumor necrosis factor alpha

[1]  A. Girbes,et al.  Augmented Procoagulant Activity in Cancer Patients, Treated with Recombinant Interferon-γ in Addition to Recombinant Tumor Necrosis Factor-α and Melphalan , 1996, Thrombosis and Haemostasis.

[2]  W. Reitsma,et al.  Lack of specific renal haemodynamic effects of different doses of dopamine after infrarenal aortic surgery. , 1996, British journal of anaesthesia.

[3]  A. Girbes,et al.  Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system. , 1996, Cancer research.

[4]  A. Girbes,et al.  High plasma tumor necrosis factor (TNF)-alpha concentrations and a sepsis-like syndrome in patients undergoing hyperthermic isolated limb perfusion with recombinant TNF-alpha, interferon-gamma, and melphalan. , 1996, Critical care medicine.

[5]  R. Allen.  Systemic Leakage and Side Effects of Tumor Necrosis Factor α Administered via Isolated Limb Perfusion Can Be Manipulated by Flow Rate Adjustment , 1996 .

[6]  D. Fraker,et al.  Treatment of patients with melanoma of the extremity using hyperthermic isolated limb perfusion with melphalan, tumor necrosis factor, and interferon gamma: results of a tumor necrosis factor dose-escalation study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  J. D. Chambers,et al.  C5a- and tumor necrosis factor-alpha-induced leukocytosis occurs independently of beta 2 integrins and L-selectin: differential effects on neutrophil adhesion molecule expression in vivo. , 1995, Blood.

[8]  R. Chioléro,et al.  Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. , 1995, Chest.

[9]  K. Pfizenmaier,et al.  Lymphocyte Adhesion to Human Endothelial Cells Induces Tissue Factor Expression via a Juxtacrine Pathway , 1995, Thrombosis and Haemostasis.

[10]  J. van der Meer,et al.  Tumor necrosis factor alpha-induced endothelial tissue factor is located on the cell surface rather than in the subendothelial matrix. , 1994, Blood.

[11]  J. L. Lerma,et al.  Involvement of tumor necrosis factor and platelet-activating factor in the pathogenesis of experimental nephrosis in rats. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[12]  Richard Peto,et al.  General Discussion: II , 1993 .

[13]  B. Beutler,et al.  A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome. , 1993, The Journal of clinical investigation.

[14]  T. van der Poll,et al.  Pathogenesis of disseminated intravascular coagulation in sepsis. , 1993, JAMA.

[15]  J. Lorente,et al.  clinical investigations in critical care Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome * , 2006 .

[16]  A. Vicente,et al.  Coagulation, fibrinolytic and kallikrein systems in neonates with uncomplicated sepsis and septic shock. , 1993, Haemostasis.

[17]  B. Bloch,et al.  Tumor necrosis factor alpha in human kidney transplant rejection--analysis by in situ hybridization. , 1993, Transplantation.

[18]  C. Alexander,et al.  Rapid measurement of blood leakage during regional chemotherapy , 1993, European Journal of Nuclear Medicine.

[19]  J. Vincent,et al.  Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. , 1993, Chest.

[20]  K. Mann,et al.  Complex-dependent inhibition of factor VIIa by antithrombin III and heparin. , 1993, The Journal of biological chemistry.

[21]  Jan Tavernier,et al.  Human TNF mutants with selective activity on the p55 receptor , 1993, Nature.

[22]  C. Sternberg,et al.  Recombinant tumor necrosis factor for superficial bladder tumors. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  S. Rapaport,et al.  Initiation and regulation of tissue factor-dependent blood coagulation. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[24]  J. Baars,et al.  Interleukin‐2 induces activation of coagulation and fibrinolysis: resemblance to the changes seen during experimental endotoxaemia , 1992, British journal of haematology.

[25]  N. Coombe,et al.  A phase I pharmacokinetic study of recombinant human tumor necrosis factor administered by a 5-day continuous infusion , 1992, Investigational New Drugs.

[26]  R. Bone,et al.  Modulators of coagulation. A critical appraisal of their role in sepsis. , 1992, Archives of internal medicine.

[27]  C. Perret,et al.  A novel score for predicting the mortality of septic shock patients , 1992, Critical care medicine.

[28]  S. Basu,et al.  Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. , 1992, Blood.

[29]  D. Schaid,et al.  Phase II Trial of Recombinant Tumor Necrosis Factor in Disseminated Malignant Melanoma , 1992, American journal of clinical oncology.

[30]  A. Costarino,et al.  Correlation of plasma cytokine elevations with mortality rate in children with sepsis. , 1992, The Journal of pediatrics.

[31]  M. Krönke,et al.  Mechanisms of tumor necrosis factor action. , 1992, Seminars in oncology.

[32]  C. Chopin,et al.  Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. , 1992, Chest.

[33]  A. Romaschin,et al.  Systemic phospholipase A2 and cachectin levels in adult respiratory distress syndrome and multiple-organ failure. , 1992, Clinical biochemistry.

[34]  B. Hazenberg,et al.  Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor, and acute‐phase proteins during the treatment of severe sepsis in humans , 1992, Critical care medicine.

[35]  G. T. Budd,et al.  Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[36]  G. Bernard,et al.  Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. , 1991, The American review of respiratory disease.

[37]  K. L. Kaplan.  Methods for assessing activation of coagulation by contrast materials or catheters. , 1991, Seminars in hematology.

[38]  M. Glauser,et al.  Septic shock: pathogenesis , 1991, The Lancet.

[39]  B. Munger,et al.  Intravascular plastic catheters. How they potentiate tumor necrosis factor release and exacerbate complications associated with sepsis. , 1991, Archives of surgery.

[40]  J. C. Murray.  Coagulation and cancer. , 1991, British Journal of Cancer.

[41]  Marcel,et al.  Fibrinolytic response to tumor necrosis factor in healthy subjects , 1991, The Journal of experimental medicine.

[42]  E. Vellenga,et al.  Tumour necrosis factor (cachectin) and other cytokines in septic shock: a review of the literature. , 1991, The Netherlands journal of medicine.

[43]  N. Mackman,et al.  The Structural Biology of Expression and Function of Tissue Factor , 1991, Thrombosis and Haemostasis.

[44]  F. Herrmann,et al.  Phase I trial of recombinant human tumour necrosis factor α in patients with advanced malignancy , 1991 .

[45]  C. Benjamin,et al.  Human monocytes bind to two cytokine-induced adhesive ligands on cultured human endothelial cells: endothelial-leukocyte adhesion molecule-1 and vascular cell adhesion molecule-1 , 1991 .

[46]  B. Storer,et al.  Biological and clinical effects of intravenous tumor necrosis factor-alpha administered three times weekly. , 1991, Cancer research.

[47]  J. Philippé,et al.  Fibrinolysis and Coagulation in Patients with Infectious Disease and Sepsis , 1991, Thrombosis and Haemostasis.

[48]  B. Brenner,et al.  Interleukin 1 induces prolonged L-arginine-dependent cyclic guanosine monophosphate and nitrite production in rat vascular smooth muscle cells. , 1991, The Journal of clinical investigation.

[49]  T. Fleming,et al.  A phase II trial of recombinant tumor necrosis factor in patients with metastatic colorectal adenocarcinoma: a Southwest Oncology Group study. , 1990, Journal of biological response modifiers.

[50]  T. Kooistra,et al.  Progress of fibrinolysis during tumor necrosis factor infusions in humans. Concomitant increase in tissue-type plasminogen activator, plasminogen activator inhibitor type-1, and fibrin(ogen) degradation products. , 1990, Blood.

[51]  W. W. Bailey,et al.  Complement activation and lung permeability during cardiopulmonary bypass. , 1990, The Annals of thoracic surgery.

[52]  N. Kemeny,et al.  A phase II trial of recombinant tumor necrosis factor in patients with advanced colorectal carcinoma , 1990, Cancer.

[53]  A. M. Lefer,et al.  Mediation of cardioprotection by transforming growth factor-beta. , 1990, Science.

[54]  J. Norton,et al.  Cachectic effects of recombinant human tumor necrosis factor in rats. , 1990, Cancer research.

[55]  T. van der Poll,et al.  Activation of coagulation after administration of tumor necrosis factor to normal subjects. , 1990, The New England journal of medicine.

[56]  V. Diehl,et al.  Phase II study of recombinant human tumor necrosis factor in colorectal carcinoma. , 1990, Journal of biological response modifiers.

[57]  C. Galanos,et al.  Induction of hypersensitivity to endotoxin and tumor necrosis factor by sublethal infection with Salmonella typhimurium , 1990, Infection and immunity.

[58]  D. Liénard,et al.  Results of 206 isolated limb perfusions for malignant melanoma. , 1989, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[59]  V. Diehl,et al.  Effects of recombinant tumor necrosis factor (rHuTNFα)on human neutrophils and monocytes: In vitro, ex vivo and in vivo , 1989, European journal of haematology.

[60]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[61]  R. Figlin,et al.  Pulmonary toxicity of recombinant human tumor necrosis factor. , 1989, Chest.

[62]  D. Spriggs,et al.  Tumor necrosis factor infusions have a procoagulant effect on the hemostatic mechanism of humans. , 1989, Blood.

[63]  W. Buurman,et al.  Plasma tumor necrosis factor and mortality in critically ill septic patients. , 1989, Critical care medicine.

[64]  Kathleen M. Smith,et al.  Localization of tissue factor in the normal vessel wall and in the atherosclerotic plaque. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[65]  N. Hogg.  The leukocyte integrins. , 1989, Immunology today.

[66]  V. Diehl,et al.  Phase I study of intratumoral application of recombinant human tumor necrosis factor. , 1989, European journal of cancer & clinical oncology.

[67]  K. Pfizenmaier,et al.  Intralesional application of recombinant human tumor necrosis factor alpha induces local tumor regression in patients with advanced malignancies. , 1989, European journal of cancer & clinical oncology.

[68]  N. Perico,et al.  Tumor necrosis factor induces glomerular damage in the rabbit. , 1989, The American journal of pathology.

[69]  W. Fiers,et al.  TUMOR NECROSIS FACTOR INCREASES THE PRODUCTION OF PLASMINOGEN ACTIVATOR INHIBITOR IN HUMAN ENDOTHELIAL CELLS IN VITRO AND IN RATS IN VIVO , 1988, Thrombosis and Haemostasis.

[70]  V. Diehl,et al.  Phase I study of 24-hour continuous intravenous infusion of recombinant human tumor necrosis factor. , 1988, Journal of biological response modifiers.

[71]  T. Shiga,et al.  Human pharmacological investigation of a human recombinant tumor necrosis factor preparation (PAC-4D) a phase-I trial. , 1988, Archiv fur Geschwulstforschung.

[72]  Y. Sohmura.  Antitumor Effect of Recombinant Human Tumor Necrosis Factor Alpha and Its Augmentation in vitro and in vivo1 , 1988 .

[73]  D. Kufe,et al.  Recombinant human tumor necrosis factor administered as a 24-hour intravenous infusion. A phase I and pharmacologic study. , 1988, Journal of the National Cancer Institute.

[74]  J F Murray,et al.  An expanded definition of the adult respiratory distress syndrome. , 1988, The American review of respiratory disease.

[75]  R. Kurzrock,et al.  A phase I trial of intravenously-administered recombinant tumor necrosis factor-alpha in cancer patients. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  J. Weinberg,et al.  Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. , 1988, Blood.

[77]  M. L. Larsen,et al.  Heparin induces release of extrinsic coagulation pathway inhibitor (EPI). , 1988, Thrombosis research.

[78]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[79]  M. Gimbrone,et al.  Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. , 1988, The Journal of biological chemistry.

[80]  D. Kufe,et al.  Recombinant human tumor necrosis factor administered as a five-day continuous infusion in cancer patients: phase I toxicity and effects on lipid metabolism. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[81]  K. Tracey,et al.  Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.

[82]  J. Gabrilove,et al.  Clinical pharmacology of recombinant human tumor necrosis factor in patients with advanced cancer. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  R. Bona,et al.  Tissue factor apoprotein: intracellular transport and expression in shed membrane vesicles. , 1987, Thrombosis research.

[84]  W. Molenaar,et al.  Results of isolated regional perfusion in the treatment of malignant soft tissue tumors of the extremities , 1987, Cancer.

[85]  M. Rosenblum,et al.  Phase I study of recombinant tumor necrosis factor in cancer patients. , 1987, Cancer research.

[86]  B. Beutler,et al.  The endogenous mediator of endotoxic shock. , 1987, Clinical research.

[87]  A. Waage,et al.  ASSOCIATION BETWEEN TUMOUR NECROSIS FACTOR IN SERUM AND FATAL OUTCOME IN PATIENTS WITH MENINGOCOCCAL DISEASE , 1987, The Lancet.

[88]  B. Beutler,et al.  Cachectin: more than a tumor necrosis factor. , 1987, The New England journal of medicine.

[89]  D. Belin,et al.  Gamma interferon enhances macrophage transcription of the tumor necrosis factor/cachectin, interleukin 1, and urokinase genes, which are controlled by short-lived repressors , 1986, The Journal of experimental medicine.

[90]  J. D. Albert,et al.  Shock and tissue injury induced by recombinant human cachectin. , 1986, Science.

[91]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[92]  J. Tavernier,et al.  Induction of the synthesis of tumor necrosis factor receptors by interferon-gamma. , 1986, Journal of immunology.

[93]  D. Stern,et al.  Modulation of endothelial cell hemostatic properties by tumor necrosis factor , 1986, The Journal of experimental medicine.

[94]  B. Aggarwal,et al.  Characterization of receptors for human tumour necrosis factor and their regulation by γ-interferon , 1985, Nature.

[95]  J. Strickler,et al.  Molecular cloning of the complementary DNA for human tumor necrosis factor. , 1985, Science.

[96]  D. Goeddel,et al.  Human tumor necrosis factor. Production, purification, and characterization. , 1985, The Journal of biological chemistry.

[97]  G. Escolar,et al.  Tissue factor in microvesicles shed from U87MG human glioblastoma cells induces coagulation, platelet aggregation, and thrombogenesis. , 1984, Blood.

[98]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[99]  O. Creech,et al.  Cancer chemotherapy by perfusion. , 1963, Advances in cancer research.

[100]  M. J. Shear,et al.  Chemical Treatment of Tumors. IX. Reactions of Mice with Primary Subcutaneous Tumors to Injection of a Hemorrhage-Producing Bacterial Polysaccharide , 1944 .

[101]  W. Coley,et al.  THE TREATMENT OF MALIGNAT TUMORS BY REPEATED INOCULATIONS OF ERYSIPELAS: WITH A REPORT OF TEN ORIGINAL CASES , 1893 .

[102]  H. Abe,et al.  Cellular and cytokine responses of the human central nervous system to intracranial administration of tumor necrosis factor α for the treatment of malignant gliomas , 2005, Cancer Immunology, Immunotherapy.

[103]  C. Hack,et al.  Coagulation disorders in septic shock , 2005, Intensive Care Medicine.

[104]  A. Mittelman,et al.  Phase I clinical trial of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[105]  S. Arbuck,et al.  A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days , 2004, Cancer Chemotherapy and Pharmacology.

[106]  A. Ho,et al.  Phase-I trial of intravenous continuous infusion of tumor necrosis factor in advanced metastatic carcinomas , 2004, Journal of Cancer Research and Clinical Oncology.

[107]  T. Taguchi,et al.  Phase I study of recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[108]  N. Niederle,et al.  Phase I study of recombinant human tumor necrosis factor α in advanced malignant disease , 2004, Cancer Immunology, Immunotherapy.

[109]  T. Shiga,et al.  Phase II clinical trial of high-dose recombinant human tumor necrosis factor , 2004, Cancer Chemotherapy and Pharmacology.

[110]  D. Fraker,et al.  Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[111]  A. D. de Vos,et al.  Inhibiting interleukin-1 and tumor necrosis factor-alpha does not reduce induction of plasminogen activator inhibitor type-1 by endotoxin in rats in vivo. , 1995, Blood.

[112]  I. Schwager,et al.  Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. , 1994, Blood.

[113]  D. Monroe,et al.  Human monocytes support factor X activation by factor VIIa, independent of tissue factor: implications for the therapeutic mechanism of high-dose factor VIIa in hemophilia. , 1994, Blood.

[114]  Steven D. Carson,et al.  Fibroblast tissue factor: calcium and ionophore induce shape changes, release of membrane vesicles, and redistribution of tissue factor antigen in addition to increased procoagulant activity. , 1994, Blood.

[115]  T. van der Poll,et al.  Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. , 1994, The Journal of clinical investigation.

[116]  E. Girardin,et al.  Early hemodynamic and renal effects of tumor necrosis factor alpha: role of thromboxane. , 1994, Circulatory shock.

[117]  K. Tracey,et al.  Tumor necrosis factor, other cytokines and disease. , 1993, Annual review of cell biology.

[118]  E. Ritz,et al.  In situ production of TNF-alpha, IL-1 beta and IL-2R in ANCA-positive glomerulonephritis. , 1993, Kidney international.

[119]  E. Eisenhauer,et al.  A phase II study of recombinant tumor necrosis factor in renal cell carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[120]  C. Scheibenbogen,et al.  Interferon-gamma-induced expression of tissue factor activity during human monocyte to macrophage maturation. , 1992, Haemostasis.

[121]  V. Serretta,et al.  Intravesical therapy of superficial bladder transitional cell carcinoma with tumor necrosis factor-alpha: preliminary report of a phase I-II study. , 1992, European urology.

[122]  M. Fink,et al.  Tumor necrosis factor-alpha causes myocardial depression in guinea pigs. , 1992, Critical care medicine.

[123]  N. Renard,et al.  High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[124]  H. Hoekstra,et al.  Continuous leakage monitoring during hyperthermic isolated regional perfusion of the lower limb: techniques and results , 1992 .

[125]  P. Schilling,et al.  Novel tumor necrosis factor toxic effects. Pulmonary hemorrhage and severe hepatic dysfunction , 1992, Cancer.

[126]  H. Tilg,et al.  Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial. , 1991, European journal of cancer.

[127]  G. Bastert,et al.  Effect of intraperitoneal recombinant human tumour necrosis factor alpha on malignant ascites. , 1991, European journal of cancer.

[128]  H. Büller,et al.  Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. , 1990, Blood.

[129]  R. Tompkins,et al.  Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. , 1990, The Journal of infectious diseases.

[130]  N. Berger,et al.  Effect of tumor necrosis factor on the human fibrinolytic system. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[131]  M. Gore,et al.  Treatment of advanced ovarian cancer with intraperitoneal tumour necrosis factor. , 1990, European journal of cancer.

[132]  S. Zuckerman,et al.  Induction of Endothelial Cell/Macrophage Procoagulant Activity: Synergistic Stimulation by Gamma Interferon and Granulocyte-Macrophage Colony Stimulating Factor , 1989, Thrombosis and Haemostasis.

[133]  T. Drake,et al.  Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis. , 1989, The American journal of pathology.

[134]  J. Kahn,et al.  Intralesional recombinant tumor necrosis factor-alpha for AIDS-associated Kaposi's sarcoma: a randomized, double-blind trial. , 1989, Journal of acquired immune deficiency syndromes.

[135]  T. Taguchi.  Phase I study of recombinant human tumor necrosis factor (rHu-TNF:PT-050). , 1988, Cancer detection and prevention.

[136]  Y. Nemerson.  Tissue factor and hemostasis. , 1988, Blood.

[137]  A. Donker,et al.  A radioisotope method for simultaneous determination of the glomerular filtration rate and the effective renal plasma flow. , 1977, The Netherlands journal of medicine.

[138]  J. Adams,et al.  hypotension: Implications for the involvement of nitric oxide , 2022 .